Business
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has joined HOPE as Medical DirectorImmediate expansion is planned in Western Florida and Palm BeachAcquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. (\"HOPE\"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), today announced the acquisition of a strategic interest in Cohen and Associates, LLC (“Cohen, LLC”) and its incorporation into the HOPE Network. Additionally, Rebecca Cohen, MD has joined HOPE as Medical Director, overseeing medical standards of care throughout HOPE’s Florida locations. Cohen, LLC is one of the premier interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Transcranial Magnetic Stimulation (“TMS”), and medication management. Dr. Cohen is an Interventional Psychiatrist and Psychopharmacologist specializing in the treatment of mood and anxiety disorders as well as a nationally recognized expert in TMS. She founded her practice in 2014 as one of the first dedicated interventional psychiatry practices in the United States. Her academic background spans Tufts University, Boston University, where she was recipient of the psychiatry department’s Malamud Award for Excellence, and Georgetown University. Dr Cohen has been honored as a Fellow of both the American Psychiatric Association and the International Clinical TMS Society. “We are excited to launch HOPE Therapeutics in Florida with Dr. Cohen’s passionate medical leadership. Her background and training perfectly complement the anesthesia and pain management expertise brought by Stephen Durand, RN, founder of Dura Medical, now a key component of HOPE. Rebecca dedicated her practice to TMS and other neuroplastic therapies when the field was in its infancy and has continued to advance the science of interventional psychiatry. Her extraordinary compassion for patients fits perfectly with our culture of bringing HOPE to life,” said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics. “I am thrilled to be assuming a leadership role in HOPE Therapeutics at a mo...